Aileron Therapeutics to Highlight Stapled Peptide Data at AACR Annual Meeting 2012

Aileron SAB Member Dr. Stephen Fesik Receives 6th Annual AACR Award for Outstanding Achievement in Chemistry in Cancer Research

CAMBRIDGE, Mass., March 30, 2012 – Aileron Therapeutics announced today that Tomi Sawyer, Ph.D., chief scientific officer and senior vice president of discovery and innovative technologies at Aileron, will - for the first time - highlight recent progress with Aileron’s joint p53 Stapled Peptides program with its partner Roche in conjunction with the American Association for Cancer Research (AACR) Annual Meeting 2012 in Chicago. Dr. Sawyer will be speaking on Saturday, March 31 at 3:45pm as part of an educational session called “Chemical Strategies for Modulating Protein-Protein Inhibition.” Aileron, along with Genentech, is one of only two companies invited to participate in this session.

Aileron also congratulates Stephen Fesik, Ph.D., member of Aileron’s Scientific Advisory Board, and professor of biochemistry, pharmacology and chemistry, and Orrin H. Ingram II Chair in Cancer Research at Vanderbilt University School of Medicine, for receiving the 6th Annual AACR Award for Outstanding Achievement in Chemistry in Cancer Research. Dr. Fesik will be recognized and deliver his award lecture entitled, “Drugging the Undruggable Using Fragment-Based Methods,” on Tuesday, April 3, at 3:00pm during the AACR meeting.

About Aileron Therapeutics
Aileron Therapeutics is the world leader in stabilized peptides. The company has built a powerful drug discovery engine centered on the multiple chemical-linking technologies comprising the company’s proprietary Stapled Peptides platform. Aileron’s platform enables the company to create drugs for important diseases that are implicated by highly sought after biological targets not well served by current small molecule or antibody approaches. Aileron’s Stapled Peptides have demonstrated their unique ability to penetrate cells throughout the body and the company is developing a portfolio of Stapled Peptide drugs for the treatment of cancer, infectious disease, metabolic disease and immune/inflammatory diseases.

With an exceptional team of drug developers, company builders and scientists, and the support of leading venture capital firms and pharmaceutical venture investors, as well as a collaboration with Roche, Aileron is turning its vision for the future of medicine into a reality. For more information, please visit www.aileronrx.com.

###